April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma
Dec 24, 2024, 14:29

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma

Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:

“Advanced urothelial carcinoma patients with TSC1 mutations show higher response rates to EV monotherapy (87% vs. 51%), while presence of CDKN2A/B is neg associated with PFS (4.6 vs. 6 ) mo. (Nectin4 is not available).”

Enfortumab

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data

Authors: Tanya Jindal et al.

Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma